Cells comprising the prostate cancer microenvironment lack recurrent clonal somatic genomic aberrations

Molecular Cancer Research

Volumn 14, Issue 4, 2016, Pages 374-384

  Bianchi Frias, Daniella ^a   Basom, Ryan ^a   Delrow, Jeffrey J ^a   Coleman, Ilsa M ^a   Dakhova, Olga ^b   Qu, Xiaoyu ^a   Fang, Min ^a   Franco, Omar E ^c   Ericson, Nolan G ^a   Bielas, Jason H ^a   Hayward, Simon W ^c   True, Lawrence ^d   Morrissey, Colm ^e   Brown, Lisha ^e   Bhowmick, Neil A ^f   Rowley, David ^b   Ittmann, Michael ^b   Nelson, Peter S ^a,d,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; FISH PROTEIN; MITOCHONDRIAL DNA; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER ASSOCIATED STROMA; CANCER GROWTH; CANCER PATIENT; CARCINOMA CELL; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DIPLOIDY; FIBROBLAST; GENOMICS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOMATIC COPY NUMBER ABERRATION; STROMA; TUMOR MICROENVIRONMENT; CHROMOSOME ABERRATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN CHROMOSOME; PROSTATE TUMOR;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84963838550     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0330     Document Type: Article

References (46)

1. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008;18:27-34.
2. Taylor RA, Risbridger GP. Prostatic tumor stroma: A key player in cancer progression. Curr Cancer Drug Targets 2008;8:490-7.
3. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D, et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009;15:3979-89.
4. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59: 5002-11.
5. Campbell I, Qiu W, Haviv I. Genetic changes in tumour microenvironments. J Pathol 2011;223:450-8.
6. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
7. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 2014;26:121-35.
8. Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998;58:23-8.
9. McCarthy RP, Zhang S, Bostwick DG, Qian J, Eble JN, Wang M, et al. Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am J Pathol 2004;165:1395-400.
10. Ashida S, Orloff MS, Bebek G, Zhang L, Zheng P, Peehl DM, et al. Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin Cancer Res 2012;18:1578-87.
11. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001;61:8135-42.
12. Taylor RW, Taylor GA, Durham SE, Turnbull DM. The determination of complete human mitochondrial DNA sequences in single cells: implications for the study of somatic mitochondrial DNA point mutations. Nucleic Acids Res 2001;29:E74-4.
13. Salas A, Yao YG, Macaulay V, Vega A, Carracedo A, Bandelt HJ. A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2005;2:e296.
14. Pugh TJ, Delaney AD, Farnoud N, Flibotte S, Griffith M, Li HI, et al. Impact of whole genome amplification on analysis of copy number variants. Nucleic Acids Res 2008;36:e80.
15. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet 2004;36:949-51.
16. Wong KK, de Leeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 2007;80:91-104.
17. Cheng I, Levin AM, Tai YC, Plummer S, Chen GK, Neslund-Dudas C, et al. Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 2012;51:66-76.
18. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
19. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, et al. Highresolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091-100.
20. Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer 2006;45:1018-32.
21. Sun J, Liu W, Adams TS, Li X, Turner AR, Chang B, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007;67:692-700.
22. Han T, Chang CW, Kwekel JC, Chen Y, Ge Y, Martinez-Murillo F, et al. Characterization of whole genome amplified (WGA) DNA for use in genotyping assay development. BMC Genomics 2012;13:217.
23. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 2001;10:1907-13.
24. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009;461:1084-91.
25. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-9.
26. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32:355-7.
27. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, et al. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 2010;70:9650-8.
28. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007;357:2543-51.
29. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
30. Campbell IG, Qiu W, Polyak K, Haviv I. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008;358:1634-5.
31. Hosein AN, Wu M, Arcand SL, Lavallee S, Hebert J, Tonin PN, et al. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 2010;70:5770-7.
32. Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, et al. Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?Breast Cancer Res Treat 2012;136:693-703.
33. Sieben NL, ter Haar NT, Cornelisse CJ, Fleuren GJ, Cleton-Jansen AM. PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol 2000;31:1414-9.
34. Aaltonen KE, Ebbesson A, Wigerup C, Hedenfalk I. Laser capture microdissection (LCM) and whole genome amplification (WGA) of DNA from normal breast tissue-optimization for genome wide array analyses. BMC Res Notes 2011;4:69.
35. Talseth-Palmer BA, Bowden NA, Hill A, Meldrum C, Scott RJ. Whole genome amplification and its impact on CGH array profiles. BMC Res Notes 2008;1:56.
36. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
37. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008;40:650-5.
38. Walter K, Omura N, Hong SM, Griffith M, Goggins M. Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biol Ther 2008;7:882-8.
39. Rummel S, Valente AL, Kane JL, Shriver CD, Ellsworth RE. Genomic (in) stability of the breast tumor microenvironment. Mol Cancer Res 2012;10:1526-31.
40. Eng C, Leone G, Orloff MS, Ostrowski MC. Genomic alterations in tumor stroma. Cancer Res 2009;69:6759-64.
41. Cai X, Evrony GD, Lehmann HS, Elhosary PC, Mehta BK, Poduri A, et al. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Rep 2014;8:1280-9.
42. McConnell MJ, Lindberg MR, Brennand KJ, Piper JC, Voet T, Cowing-Zitron C, et al. Mosaic copy number variation in human neurons. Science 2013;342:632-7.
43. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015;47: 367-72.
44. Jeschke J, Collignon E, Fuks F. DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment. FEBS J 2015;282:1801-14.
45. Banerjee J, Mishra R, Li X, Jackson RS2nd, Sharma A, Bhowmick NA. A reciprocal role of prostate cancer on stromal DNA damage. Oncogene 2014;33:4924-31.
46. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899-905.